Aim: To analyze the predictive value of the dynamic risk stratification (DRS) system for assessing the risk of recurrent/persistent disease in our large group of differentiated thyroid carcinoma (DTC) patients.
Patients And Methods: We retrospectively included 2184 consecutive patients who received radioiodine ablation therapy following a total or near total thyroidectomy in our department between 1998 and 2014. The American Thyroid Association (ATA) classification was used for initial risk classification. At the second year of follow-up period after radioiodine ablation therapy, DRS was performed also. The ATA and DRS risk classification results were compared with clinical outcome.
Results: According to DRS, more than half of the ATA high-risk patients (73.2%) moved to the DRS low-risk category and the 6.4% of ATA low-risk patients comprised the DRS high-risk category. In comparison of variables within the ATA and the DRS risk groups with clinical outcome, combined use of the ATA and the DRS systems was statistically significant to predict the recurrent/persistent disease (P<0.005).
Conclusion: The present study revealed that the DRS system is a necessary stratification system in addition to the initial risk evaluation. The DRS can discriminate those patients who does not require closer follow-up in the long-term period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MNM.0000000000000766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence.
Clin Endocrinol (Oxf)
September 2024
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Objective: The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.
Design: Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.
Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer.
Cancers (Basel)
September 2023
Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Background: In recent years, there has been a renewed interest in thyroid cancer management paradigms that use individualized risk assessments as the basis for treatment and follow-up recommendations. In this study, we assumed that the long-term follow-up of differentiated thyroid cancer patients might be better tailored by integrating the response to initial therapy with the America Thyroid Association (ATA) risk classes.
Methods: This retrospective study included low- and intermediate-risk papillary thyroid cancer (PTC) patients followed up for a median time of 8 years and classified according to the response to initial therapy assessed 6-12 months after initial treatment.
Arrhythmia and Survival Outcomes Among Black Patients and White Patients With a Primary Prevention Defibrillator.
Circulation
July 2023
Clinical Cardiovascular Research Center, University of Rochester Medical Center, NY (A.Y., S.A., S.M., B.P., M.K.A., V.K., W.Z., Ilan Goldenberg).
Article Synopsis
- Black Americans with nonischemic cardiomyopathy (NICM) have a higher risk of tachyarrhythmias and complications related to implantable cardioverter-defibrillators (ICDs) compared to White Americans.
- The study found that Black patients were younger, more likely to be female, and had more comorbidities, contributing to their increased risk for first ventricular tachyarrhythmias and ICD therapies.
- Despite the higher risks in NICM cases, both Black and White patients showed similar benefits from ICDs in ischemic cardiomyopathy.
Differentiated Thyroid Cancer in a Pediatric Population: Estimating the Risk of Recurrence and Evolution Over Time.
Cureus
January 2023
Endocrinology, Hospital CUF Cascais, Lisboa, PRT.
Background Differentiated thyroid cancer (DTC) is the most common endocrine cancer during childhood, and the prognosis is usually good. The 2015 American Thyroid Association (ATA) pediatric guidelines for DTC classify patients into three categories (low, intermediate, and high) that represent the risk for persistent/recurrent disease. The "Dynamic Risk Stratification" (DRS) System showed that, in adults, reassessment of disease status during follow-up was a better predictor of disease status at the end of follow-up when compared to ATA risk stratification.
View Article and Find Full Text PDFValidation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study.
Front Endocrinol (Lausanne)
January 2023
Ciber de Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Introduction: The dynamic risk stratification (DRS) is a relatively new system in thyroid cancer that considers the response to primary treatment to improve the initial risk of recurrence. We wanted to validate DRS system in a nationwide multicenter study and explore if the incorporation of BRAFV600E into DRS helps to better categorize and predict outcomes.
Materials And Methods: Retrospective study of 685 patients from seven centers between 1991 and 2016, with a mean age of 48 years and a median follow-up time of 45 months (range 23-77).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!